AONC — American Oncology Network Balance Sheet
0.000.00%
- $610.42m
- $713.96m
- $1.76bn
- 38
- 51
- 53
- 44
Annual balance sheet for American Oncology Network, fiscal year end - December 31st, millions except per share.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | |
| Standards: | — | USG | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | — | 27.4 | 36.8 | 63.9 | 72.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 138 | 166 | 165 | 190 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | — | 208 | 242 | 278 | 331 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 32.6 | 75.7 | 83.8 | 98.5 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | — | 248 | 326 | 374 | 470 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | — | 119 | 141 | 169 | 217 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | — | 189 | 264 | 471 | 452 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | — | 59.5 | 62 | -96.7 | 18.8 |
| Total Liabilities & Shareholders' Equity | — | 248 | 326 | 374 | 470 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |